チリダニ類アレルギー(House Dust Mite Allergy):治療薬開発パイプライン動向(世界、2015年上半期版)

◆英語タイトル:House Dust Mite Allergy - Pipeline Review, H1 2015
◆商品コード:GMDHC6200IDB
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2015年1月30日
◆ページ数:54
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥220,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD4,000 ⇒換算¥440,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD6,000 ⇒換算¥660,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。Global Markets Direct社の概要及び新刊レポートはこちらでご確認いただけます。

当調査レポートでは、世界におけるチリダニ類アレルギー(House Dust Mite Allergy)の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。

・イントロダクション
・チリダニ類アレルギー(House Dust Mite Allergy)の概要
・チリダニ類アレルギー(House Dust Mite Allergy)治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・チリダニ類アレルギー(House Dust Mite Allergy)パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・製品
・大学/研究機関別、研究中の製品
・チリダニ類アレルギー(House Dust Mite Allergy)治療薬開発に取り組んでいる企業:企業別製品パイプライン
・チリダニ類アレルギー(House Dust Mite Allergy)治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

House Dust Mite Allergy – Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘House Dust Mite Allergy – Pipeline Review, H1 2015’, provides an overview of the House Dust Mite Allergy’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for House Dust Mite Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for House Dust Mite Allergy and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of House Dust Mite Allergy
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for House Dust Mite Allergy and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the House Dust Mite Allergy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the House Dust Mite Allergy pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for House Dust Mite Allergy
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding House Dust Mite Allergy pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
House Dust Mite Allergy Overview 6
Therapeutics Development 7
Pipeline Products for House Dust Mite Allergy – Overview 7
Pipeline Products for House Dust Mite Allergy – Comparative Analysis 8
House Dust Mite Allergy – Therapeutics under Development by Companies 9
House Dust Mite Allergy – Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
House Dust Mite Allergy – Products under Development by Companies 13
House Dust Mite Allergy – Companies Involved in Therapeutics Development 14
ALK-Abello A/S 14
Anergis SA 15
Biomay AG 16
Circassia Pharmaceuticals plc 17
DBV Technologies S.A. 18
HAL Allergy BV 19
Stallergenes S.A. 20
House Dust Mite Allergy – Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Target 22
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
AllerDM – Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Allergen for House Dust Mites Induced Allergic Rhinitis and Rhinoconjunctivitis – Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
allergenic pollen extract of timothy – Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
BM-35 – Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
House Dust Mite-SPIRE – Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
MK-8237 – Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
PL-103 – Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
S-524101 – Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Viaskin House Dust Mite – Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
House Dust Mite Allergy – Recent Pipeline Updates 39
House Dust Mite Allergy – Dormant Projects 43
House Dust Mite Allergy – Discontinued Products 44
House Dust Mite Allergy – Product Development Milestones 45
Featured News & Press Releases 45
Jun 16, 2014: ALK’s Partner for Japan Announces Trial Results for House Dust Mite SLIT-Tablet 45
Mar 20, 2014: ALK’s Partner Merck Initiates Phase III Clinical Development Programme in North America with the New Allergy Immunotherapy Tablet 45
Mar 20, 2014: House dust mite SLIT-tablet enters Phase III clinical development 46
Mar 04, 2014: Merck Announces Results from Phase 2b Study of MK-8237, an Investigational House Dust Mite Sublingual Allergen Immunotherapy Tablet 47
Sep 12, 2013: Circassia’s house dust mite allergy treatment achieves long-term symptom reduction 48
Jul 11, 2013: Positive results from pivotal Phase III trial of new allergy immunotherapy tablet against house dust mite-induced allergic asthma 49
Jun 19, 2013: Anergis Files Provisional US Patent On AllerDM Dust Mite Allergy Treatment 50
Jun 19, 2013: ALK-Abello’s New Allergy Immunotherapy Tablet Meets Primary Endpoint In Pivotal Phase III Trial In Patients With House Dust Mite Allergy 51
Nov 14, 2012: DBV Technologies Launches Third Viaskin Program For Treatment Of House Dust Mites Allergy In Young Children 51
Oct 10, 2012: Merck Plans To Initiate Phase III Clinical Trial With HDM AIT In North America 52
Appendix 53
Methodology 53
Coverage 53
Secondary Research 53
Primary Research 53
Expert Panel Validation 53
Contact Us 53
Disclaimer 54

[List of Tables]
Number of Products under Development for House Dust Mite Allergy, H1 2015 7
Number of Products under Development for House Dust Mite Allergy - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Comparative Analysis by Late Stage Development, H1 2015 10
Comparative Analysis by Clinical Stage Development, H1 2015 11
Comparative Analysis by Early Stage Development, H1 2015 12
Products under Development by Companies, H1 2015 13
House Dust Mite Allergy - Pipeline by ALK-Abello A/S, H1 2015 14
House Dust Mite Allergy - Pipeline by Anergis SA, H1 2015 15
House Dust Mite Allergy - Pipeline by Biomay AG, H1 2015 16
House Dust Mite Allergy - Pipeline by Circassia Pharmaceuticals plc, H1 2015 17
House Dust Mite Allergy - Pipeline by DBV Technologies S.A., H1 2015 18
House Dust Mite Allergy - Pipeline by HAL Allergy BV, H1 2015 19
House Dust Mite Allergy - Pipeline by Stallergenes S.A., H1 2015 20
Assessment by Monotherapy Products, H1 2015 21
Number of Products by Stage and Target, H1 2015 22
Number of Products by Stage and Route of Administration, H1 2015 24
Number of Products by Stage and Molecule Type, H1 2015 26
House Dust Mite Allergy Therapeutics - Recent Pipeline Updates, H1 2015 39
House Dust Mite Allergy - Dormant Projects, H1 2015 43
House Dust Mite Allergy - Discontinued Products, H1 2015 44

[List of Figures]
Number of Products under Development for House Dust Mite Allergy, H1 2015 7
Number of Products under Development for House Dust Mite Allergy - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Comparative Analysis by Late Stage Development, H1 2015 10
Comparative Analysis by Early Stage Products, H1 2015 12
Assessment by Monotherapy Products, H1 2015 21
Number of Products by Top 10 Routes of Administration, H1 2015 23
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 23
Number of Products by Top 10 Molecule Types, H1 2015 25
Number of Products by Stage and Top 10 Molecule Types, H1 2015 26

【掲載企業】

ALK-Abello A/S
Anergis SA
Biomay AG
Circassia Pharmaceuticals plc
DBV Technologies S.A.
HAL Allergy BV
Stallergenes S.A.

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ チリダニ類アレルギー(House Dust Mite Allergy):治療薬開発パイプライン動向(世界、2015年上半期版)(House Dust Mite Allergy - Pipeline Review, H1 2015)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆